| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A therapeutic role for BLyS antagonists
|
Stohl, W
|
|
2004
|
13 |
5 |
p. 317-322
|
artikel
|
| 2 |
Autologous stem cell transplantation for systemic lupus erythematosus
|
Jayne, D
|
|
2004
|
13 |
5 |
p. 359-365
|
artikel
|
| 3 |
B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells
|
Looney, R J
|
|
2004
|
13 |
5 |
p. 381-390
|
artikel
|
| 4 |
Clinical trial design in systemic lupus erythematosus: lessons learned and future directions
|
Strand, V
|
|
2004
|
13 |
5 |
p. 406-411
|
artikel
|
| 5 |
Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus
|
Dörner, T
|
|
2004
|
13 |
5 |
p. 283-289
|
artikel
|
| 6 |
CTLA4Ig: a novel inhibitor of costimulation
|
Dall’Era, M
|
|
2004
|
13 |
5 |
p. 372-376
|
artikel
|
| 7 |
Cyclophosphamide: new approaches for systemic lupus erythematosus
|
Petri, M
|
|
2004
|
13 |
5 |
p. 366-371
|
artikel
|
| 8 |
Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
|
Gorman, C
|
|
2004
|
13 |
5 |
p. 312-316
|
artikel
|
| 9 |
Gene therapy in systemic lupus erythematosus
|
Kyttaris, V C
|
|
2004
|
13 |
5 |
p. 353-358
|
artikel
|
| 10 |
Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus
|
Rother, R P
|
|
2004
|
13 |
5 |
p. 328-334
|
artikel
|
| 11 |
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
|
Sidiropoulos, P I
|
|
2004
|
13 |
5 |
p. 391-397
|
artikel
|
| 12 |
LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus
|
Wallace, D J
|
|
2004
|
13 |
5 |
p. 323-327
|
artikel
|
| 13 |
LJP 1082: a toleragen for Hughes syndrome
|
Merrill, J T
|
|
2004
|
13 |
5 |
p. 335-338
|
artikel
|
| 14 |
Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus
|
Utz, P J
|
|
2004
|
13 |
5 |
p. 304-311
|
artikel
|
| 15 |
New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus
|
Manzi, S
|
|
2004
|
13 |
5 |
p. 298-303
|
artikel
|
| 16 |
Predictive value of autoantibodies for activity of systemic lupus erythematosus
|
Reveille, J D
|
|
2004
|
13 |
5 |
p. 290-297
|
artikel
|
| 17 |
Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?
|
Schiffenbauer, J
|
|
2004
|
13 |
5 |
p. 398-405
|
artikel
|
| 18 |
Rationale for interleukin-6 blockade in systemic lupus erythematosus
|
Tackey, E
|
|
2004
|
13 |
5 |
p. 339-343
|
artikel
|
| 19 |
Targeting interferon-α: a promising approach for systemic lupus erythematosus therapy
|
Schmidt, K N
|
|
2004
|
13 |
5 |
p. 348-352
|
artikel
|
| 20 |
The role of CD40 ligand in systemic lupus erythematosus
|
Yazdany, J
|
|
2004
|
13 |
5 |
p. 377-380
|
artikel
|
| 21 |
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention
|
Aringer, M
|
|
2004
|
13 |
5 |
p. 344-347
|
artikel
|
Tijdschrift beschrijving